He said Compass is happy with its current portfolio, but with M&A activity primed to heat up this year after only a modest recovery in 2024, the company plans to be aggressive in its capital ...

Compass, Anywhere Advisors, eXp Realty and HomeServices of America continue to perform, 2025 RealTrend Verified Brokerage ...

Nasdaq Insider Activity page provides trading information of corporate insiders (officers, directors and any beneficial owners of more than 10% of a class of the company’s equity securities).

The ongoing COMPANION-002 trial has been evaluating the candidate, tovecimig (formerly CTX-009), alongside paclitaxel in ...

Leerink analyst Andrew Berens upgraded Compass Therapeutics (CMPX) to Outperform from Market Perform with a price target of $6, up from $4, ...